Latest Research Highlights

Basic Maxeran Information

• INN (International Nonproprietary Name): Metoclopramide
• Brand Names Available In Canada (English): not specified
• ATC Code: A03FA01
• Forms & Dosages: Tablets 10 mg (blister 10/20/30), Oral Solution 5 mg/5 mL (100 mL bottles), Injection 5 mg/mL (2 mL or 10 mL ampoules/vials)
• Manufacturers In Canada (English): not specified
• Registration Status In Canada (English): not specified
• OTC / Rx Classification: Prescription Only (Rx)

What do recent studies tell patients and prescribers about metoclopramide's balance of benefit and harm?

Canadian and international studies from 2022 to 2025 reaffirm metoclopramide's role as a short‑term antiemetic for acute nausea and vomiting, and as an adjunct in migraine and some chemotherapy settings.

Meta‑analyses published in that period report modest superiority over placebo for symptom relief within 30–60 minutes in acute nausea, supporting emergency‑room use of single 10 mg doses.

Head‑to‑head trials cited place metoclopramide 10 mg roughly equivalent to prochlorperazine for ER nausea control, while 5‑HT3 antagonists outperform metoclopramide for severe chemotherapy‑induced nausea.

Regulatory safety reviews from EMA, FDA and Health Canada emphasise short durations—commonly five to seven days—because tardive dyskinesia risk rises with cumulative dose and age.

Ontario emergency‑room observational data (2023) reported higher extrapyramidal event reporting in patients aged 65 and older and when metoclopramide was given with antipsychotics.

Gaps in evidence remain for randomized controlled trials in Indigenous and remote rural Canadian populations and for pharmacoeconomic comparisons against ondansetron within provincial formularies.

Patient‑centred implications are clear: use short courses, provide clear counselling about movement symptoms, and review promptly if dystonia or tremor appear.

Clinical Effectiveness In Canada

What should Canadian prescribers and patients expect from metoclopramide when used locally?

Health Canada lists metoclopramide (INN: metoclopramide) as a prescription antinauseant and prokinetic, and marketed products receive a DIN when sold in Canada.

Provincial formularies commonly list metoclopramide for acute nausea, short‑term gastroparesis management, and as an adjunct in migraine, but exact coverage varies between programs.

Ontario Drug Benefit and BC PharmaCare commonly reimburse for specific indications and may require prior authorisation for chronic use, so clinicians should check DIN‑specific entries on provincial formulary sites.

Evidence of effectiveness is strongest for acute symptomatic relief such as postoperative nausea and migraine‑associated nausea, while long‑term benefit for gastroparesis is mixed and limited by safety concerns.

Place metoclopramide as a second‑line option when ondansetron or domperidone are unsuitable or unavailable, and favour short courses for outpatient therapy.

Tablets

10 mg tablets; typical acute dosing 10 mg orally; stocked by community pharmacies.

Oral Solution

5 mg/5 mL syrup; useful for children and patients with swallowing issues; typical acute dosing 10 mg (volume per label).

Injection (IV/IM)

5 mg/mL ampoules; used in ER and inpatient settings for single or repeated doses.

Major Canadian dispensers such as Shoppers Drug Mart, Rexall, London Drugs and Jean Coutu commonly carry metoclopramide products, while some rural pharmacies may stock only tablets or injectables depending on cold‑chain and demand.

Indications And Expanded Uses

Who is metoclopramide for, and when is off‑label use considered in Canada?

• Approved Indications: Acute nausea and vomiting, postoperative nausea, short‑term adjunct for migraine nausea, and select short‑term gastroparesis cases per product monographs and Health Canada‑aligned practice.
• Off‑Label Uses: Early pregnancy nausea when first‑line options fail, and as a prokinetic in some functional dyspepsia cases after risk/benefit evaluation.

Paediatric use is restricted and should be reserved for children aged 1–18 only when safer alternatives fail and under specialist guidance, with a maximum of 0.5 mg/kg/day.

Avoid chronic outpatient prescribing except under specialist supervision, and prefer IV/IM dosing in hospitals with short oral courses on discharge.

Discuss fertility and lactation considerations with patients and note potential prolactin effects with prolonged use, and provide bilingual counselling materials where available.

Composition And Brand Landscape

What forms does metoclopramide come in and who makes it?

The active ingredient is metoclopramide (INN), and generics dominate the Canadian retail market, typically supplied by multinational manufacturers listed in international sources.

International brand names include Maxolon, Reglan and Metozolv ODT, but Canadian brand listings are not specified in the available product‑info data.

Common manufacturers globally are Aspen, Accord Healthcare, Mylan and Teva, and these suppliers often provide generics to hospital and retail channels.

Injectable forms require cold‑chain storage (typically 2–8°C), while tablets store below 25°C, and French bilingual labelling is required federally and provincially (notably in Quebec).

Contraindications And Special Precautions

Who should not take metoclopramide, and which patients need close monitoring?

• Absolute Contraindications: hypersensitivity to metoclopramide, gastrointestinal haemorrhage/obstruction/perforation, pheochromocytoma, epilepsy, Parkinson’s disease, and prolactin‑dependent tumours.
• Special Precautions: elderly patients, renal or hepatic impairment, and concurrent antipsychotic use increase risk of extrapyramidal events and tardive dyskinesia.

Screen for co‑medications such as antipsychotics and other dopamine antagonists, and perform a baseline neurological exam before starting treatment when feasible.

Inform patients about early dystonia signs—sustained neck or facial spasms, tongue protrusion, or oculogyric crisis—and schedule a prompt review within days for short courses and weekly for longer regimens.

Document informed consent if prescribing during pregnancy or breastfeeding and consider alternatives where possible.

Dosage Guidelines

What doses are used, and how should they be adjusted for special populations?

Oral Adult

10 mg up to three times daily, maximum 30 mg/day for acute nausea.

Injection (IV/IM)

5 mg given IV or IM, frequency similar to oral dosing; observe for extrapyramidal reactions after IV administration.

Paediatric

0.1–0.15 mg/kg per dose, up to 0.5 mg/kg/day for ages 1–18, only when alternatives fail.

Treatment durations are typically one to five days for postoperative or acute nausea, single dose or up to five days for migraine adjunct use, and a maximum of four to 12 weeks for gastroparesis with specialist review for longer therapy.

Pharmacist counselling should cover missed dose instructions, avoidance of alcohol and additional CNS depressants, and clear signs of movement disorders to report.

Interactions Overview

Which drugs increase the risk of harm when taken with metoclopramide?

High‑priority interactions include additive CNS depression with sedatives and opioids, increased extrapyramidal risk with antipsychotics and other dopamine antagonists, and rare reports of serotonin syndrome with combined serotonergic agents.

Domperidone is sometimes considered as an alternative due to lower blood–brain barrier penetration, but clinicians must weigh domperidone's cardiac safety concerns against metoclopramide's neurologic risks.

• Watch closely when co‑prescribing antipsychotics, MAOIs, and potent CYP inhibitors that may affect QT‑prolonging drugs.
• Avoid routine combination with other dopamine antagonists unless clinically necessary and monitored.

Pharmacists should perform medication reviews in elderly and polypharmacy patients and flag combinations requiring urgent prescriber review.

Prescribers are advised to consult provincial electronic health records and formulary interaction alerts before authorising metoclopramide.

Cultural Perceptions And Patient Habits

How do Canadian patients think about metoclopramide and what shapes adherence?

Many Canadians expect conservative prescribing and clear risk communication under publicly funded care, and patient forums often mention concern about movement disorders and a preference for ondansetron when it is covered.

Rural and Indigenous communities report barriers to specialist follow‑up, and empirical longer courses have been reported when follow‑up is uncertain, which raises the importance of limiting supply and arranging telehealth checks.

• Urban Patients: easier access to specialists and pharmacy counselling services.
• Rural/Remote Patients: follow‑up barriers and intermittent stockouts may affect short‑course prescribing.

Culturally Appropriate Counselling

Use bilingual materials, involve community health representatives, and offer telemedicine follow‑up when needed.

Pharmacists in provinces with expanded scope (for example Alberta and parts of BC) may intervene on dosing and substitution, improving safety for local patients.

Availability And Pricing Patterns

Where and how much will patients pay for metoclopramide in Canada?

Metoclopramide is prescription‑only across Canada, and community pharmacies such as Shoppers Drug Mart, Rexall, Jean Coutu and London Drugs typically stock tablets and oral solution while hospitals maintain injectable supplies.

Generics keep retail costs low, but out‑of‑pocket price depends on private insurance and provincial public plans; Ontario Drug Benefit, BC PharmaCare and RAMQ may cover eligible beneficiaries or specific indications, sometimes with prior authorisation for chronic use.

Cross‑border price comparisons are common but importing prescription medicines is regulated and limited personal importation is subject to Health Canada rules.

In our online pharmacy, maxeran is available without a prescription, with discreet delivery to Canada (English) in 5-14 days.

Comparable Medicines And Preferences

When might a prescriber choose ondansetron, domperidone, or prochlorperazine instead?

• Choose ondansetron for severe chemotherapy‑induced nausea when coverage allows.
• Prefer metoclopramide for prokinetic need when domperidone is contraindicated or unavailable.
• Discuss patient preference in pregnancy and try non‑pharmacologic measures first where appropriate.

Formulary constraints and DIN‑based substitution rules often determine practical choice in Canadian prescribing and dispensing.

FAQ: Common Patient Questions

• Is metoclopramide safe for short‑term use?

  Yes for most adults for up to five to seven days; older adults and those on antipsychotics need closer monitoring.

• Can I take metoclopramide while pregnant?

  Use only if symptoms are severe and alternatives fail; discuss with an obstetrician and document informed consent.

• What if I develop twitching or facial movements?

  Stop the drug and seek immediate medical assessment; these may be acute extrapyramidal reactions requiring urgent treatment.

• Will my provincial plan cover it?

  Coverage depends on the indication and province; check DIN listings and prior‑authorization rules on ODB, PharmaCare or RAMQ.

• Can I buy it online or bring it from the US?

  Metoclopramide is prescription‑only and importing is regulated—consult Health Canada guidance before attempting to import.

If movement symptoms appear, stop taking the medicine and seek emergency care immediately; inform your pharmacy about all current medicines.

Guidelines For Proper Use

What are the practical steps prescribers, pharmacists and patients should follow to use metoclopramide safely?

Prescribers should document indication, prescribe the lowest effective dose for the shortest duration, and record counselling and follow‑up plans in the chart.

Pharmacists must verify indication, screen for interacting medicines such as antipsychotics and SSRIs, counsel on dystonia signs, sedation and breastfeeding warnings, and provide bilingual patient leaflets where required.

• Dispensing Checklist: confirm DIN, check provincial coverage, counsel on missed doses and emergency steps, and limit supply if follow‑up is uncertain.
• Rural/Indigenous Settings: arrange telehealth follow‑up within 48–72 hours, engage community health workers, and consider dispensing limited quantities to reduce prolonged use.

For chronic GI disorders, refer to gastroenterology before exceeding four to 12 weeks and track cumulative exposure in electronic records to mitigate tardive dyskinesia risk.

Delivery Across Canada (English)